Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
October 06 2022 - 7:00AM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced two
poster presentations at
the upcoming 29th Annual Meeting of
the European Society of Gene & Cell
Therapy (ESGCT) in cooperation with the British Society
of Gene & Cell Therapy (BSGCT) taking place
in Edinburgh, Scotland from October 11-14,
2022.
Poster Presentation
Details
- P238: Assessment of Safety and
Biodistribution of a miniMECP2 AAV9 Vector for Gene-replacement
Therapy of Rett Syndrome in Non-human Primates (NHPs)Presenter –
Dirk Schmitt, Senior Director of Medical Affairs, Taysha Gene
TherapiesDate and Time – Thursday, October 13th at 17:30 GMT +
1/12:30 PM Eastern TimeLocation – Cromdale
Hall
- P206: Assessment of Safety of miniMECP2
AAV9 vector (TSHA-102) for Gene-replacement Therapy of Rett
Syndrome in RatsPresenter – Dirk Schmitt, Senior Director of
Medical Affairs, Taysha Gene TherapiesDate and Time – Thursday,
October 13th at 17:30 GMT + 1/12:30 PM Eastern TimeLocation
– Cromdale Hall
Additional details can be found
at the ESGCT 29th Annual
Meeting website. About Taysha Gene
Therapies Taysha Gene Therapies
(Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease.
With a singular focus on developing curative medicines, we aim to
rapidly translate our treatments from bench to bedside. We have
combined our team’s proven experience in gene therapy drug
development and commercialization with the world-class UT
Southwestern Gene Therapy Program to build an extensive, AAV gene
therapy pipeline focused on both rare and large-market indications.
Together, we leverage our fully integrated platform—an engine for
potential new cures—with a goal of dramatically improving patients’
lives. More information is available
at www.tayshagtx.com. Company
Contact:Kimberly Lee, D.O. Chief Corporate Affairs
Officer Taysha
Gene Therapiesklee@tayshagtx.com Media
Contact: Carolyn Hawley Evoke
Canalecarolyn.hawley@evokegroup.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024